EORTC 1217
Research type
Research Study
Full title
Evaluation of 3'-deoxy-3'-[18F]fluorothymidine -PET and diffusion weighted imaging -MRI in patients with early stage non-small cell lung cancer treated with a platinum-based doublet as preoperative chemotherapy.
IRAS ID
173233
Contact name
Nandita deSouza
Contact email
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
This is a multicentre, non-randomised, prospective study in which patients with operable non-small cell lung cancer (NSCLC) will have Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) and positron emission tomography-computed tomography (PET-CT) imaging before and after chemotherapy, prior to surgical removal of their tumour. We plan to assess the accuracy of these imaging techniques, by performing imaging before and after chemotherapy and prior to surgery, comparing measurements from imaging with pathological analysis of the samples removed during surgery.
The aim is to demonstrate that DW-MRI and PET-CT techniques can provide an accurate assessment NSLCL tumour response to chemotherapy. When effective, chemotherapy induces cancer cell death and reduces the rate of cell growth. In previous studies of tumour types other than NSCLC, DW-MRI has been shown to identify cell death following chemotherapy. Furthermore, the thymidine PET-CT technique is sensitive to cell growth or proliferation. If successful, these imaging techniques will be useful in assessing chemotherapy efficacy, potentially allowing doctors to identify patients that are responding to treatment earlier than is possible with the imaging techniques that are currently used.REC name
London - Chelsea Research Ethics Committee
REC reference
15/LO/0882
Date of REC Opinion
23 Jun 2015
REC opinion
Favourable Opinion